Opioid receptors are fantastic targets for treating pain—but unfortunately, the drugs that target them can be addictive. Because the molecules suppress breathing and heart function, those drugs can ...
Septerna will use its $150 million fundraise to push forward an oral small-molecule PTH1R agonist. (iStock / Getty Images Plus) Septerna has secured $150 million in a series B fundraise, money that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results